News"Shows no effect on omicron" - WHO backtracks on...

"Shows no effect on omicron" – WHO backtracks on antibody cocktail

Corona drugs are considered a beacon of hope in the fight against the pandemic. Antibody therapy has now proven to be ineffective against the omicron variant.

Geneva – There are now remedies against Covid-19. Antibody therapies for corona infected people were considered particularly promising. However, Omikron turns things upside down. According to new studies, an antibody cocktail recommended by the World Health Organization (WHO) does not help in corona patients who are infected with the omicron variant. This is the drug from the pharmaceutical company Regeneron with the two antibodies Casirivimab and Imdevimab – a so-called antibody cocktail.

Antibody cocktail ineffective at Omicron

“It looks like this antibody cocktail shows a lack of efficacy against omicrons,” said Janet Diaz, WHO expert on the treatment of Covid-19, in Geneva on Friday. The WHO guidelines on use would be adjusted accordingly in the course of February.

In Germany, a specialist group at the Robert Koch Institute (RKI) continuously evaluates drug therapies. Expert knowledge is intended to provide a practical overview of possible therapeutics (“from clinicians for clinicians”), as can be read in an evaluation. Experts from various disciplines are represented. In an evaluation of January 6, 2022, the specialist group classified the antibody cocktail at Omikron as “not effective”.

The WHO had recommended the preparations casirivimab and imdevimab for two patient categories: those who are infected and not yet seriously ill, but have a high risk of having to go to the hospital – such as the elderly, those who have previously been ill and those who have not been vaccinated. The preparations for seriously ill Covid-19 patients who have not developed antibodies against the coronavirus were also recommended.

Effective Covid-19 drugs according to the WHO: baricitinib and sotrovimab

Two other drugs that the WHO only recommended in January for the treatment of Covid 19 patients are still effective according to current knowledge, said Diaz. These are the active ingredient baricitinib, which was originally developed to treat rheumatoid arthritis, and sotrovimab. Sotrovimab – trade name Xevudy – is a monoclonal antibody that works well against omicron. The demand is therefore high. The federal government has ordered over 50,000 cans from manufacturer GlaxoSmithKline.

  • Active substance baricitinib – originally used to treat rheumatoid arthritis
  • Sotrovimab – monoclonal antibodies GlaxoSmithKline

The WHO advised against the use of two other drugs, ruxolitinib and tofacitinib. Small studies have so far shown no benefit, and serious side effects could develop with tofacitinib, the WHO said in January.

Pill against Corona – antiviral drug Paxlovid

Hopes also rest on the new antiviral drugs such as Paxlovid* and Molnupiravir* – the first pills against Corona. (ml/dpa) * is an offer from IPPEN.MEDIA

About 30% of COVID patients develop 'persistent COVID'

'Persistent COVID', around 30% of COVID patients have developed it A new study exposes who are most at risk of suffering from this condition.

For the first time since the end of January: Corona incidence in Germany falls...

The seven-day incidence in Germany has fallen to 876.5. However, not all corona data is reported in full on weekends and public holidays. All news in the ticker.

5,500 new species of RNA viruses discovered in the oceans

RNA viruses have been around for billions of years and are responsible for diseases such as the common cold, mumps or COVID-19.

Corona in Austria: does the mask requirement fall before Easter?

In Austria, the number of corona infections is falling everywhere. The desire to return to normality is great. Will the FFP2 mask requirement fall before Easter?

What is the most likely origin of the COVID-19 pandemic?

Although we still have many questions about how the pandemic caused by SARS-CoV-2 was triggered, the jump from bats to humans is the most likely option.